Clinical investigation of gastric MALT lymphoma.
- Author:
Ji Hyang KIM
1
;
Won Seog KIM
;
Young Hyeh KO
;
Seo Young SONG
;
Sung Yong OH
;
Kihyun KIM
;
Eun Mi NAM
;
Hyun Sik JEONG
;
Sung Soo YOON
;
Hong Ghi LEE
;
Won Ki KANG
;
Chan Hyung PARK
;
Hee Jung SON
;
Jae Joon KIM
;
Jong Chul RHEE
;
Yong Il KIM
;
Dae Yong KIM
;
Howe J REE
;
Keunchil PARK
Author Information
1. Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Lymphoma, Mucosa-Associated Lymphoid Tissue;
Stomach
- MeSH:
Abdominal Pain;
Drug Therapy;
Dyspepsia;
Female;
Follow-Up Studies;
Helicobacter pylori;
Hemorrhage;
Humans;
Lymphoid Tissue;
Lymphoma;
Lymphoma, B-Cell, Marginal Zone*;
Male;
Radiotherapy;
Retrospective Studies;
Stomach;
Survival Rate
- From:Korean Journal of Medicine
2001;61(4):417-423
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach has recently been defined as a distinct clinicopathologic entity, often associated with Helicobacter pylori (H. pylori) infection. Characteristics and treatment outcomes of 57 patients with gastric MALT lymphoma were analyzed. METHODS: Retrospective analysis of 57 cases of gastric MALT lymphoma who underwent treatment with various modalities at Samsung Medical Center from Mar. 1995 to Jul. 2000 was performed. RESULTS: The median age of the patients was 47 years (ranged from 22 to 75 years) and the ratio of males to females was 1.1:1. The presenting symptoms were abdominal pain, indigestion and GI bleeding. By Modified Ann Arbor system, stage IE accounted for 70.2%, stage II1E 14.0%, stage II2E 14.0%, and stage IV 1.8%, respectively. H. pylori had been evaluated histologically in 49 cases of which 81.6% was positive. Low grade histology accounted for 71.9% and high grade histology 28.1%. Treatment modalities included H. pylori eradication, surgery, chemotherapy, radiotherapy and their combination therapy. In one case, the patient was observed without treatment. Complete remission rate was 98.2%. H. pylori eradication alone resulted in lymphoma regression successfully in 20 out of 23 patients. With median follow-up of 33 months (3-61 months), median survival was not reached. Overall 3 year survival rate was 94.7%. CONCLUSION: Regardless of treatment modality, high survival rate (3 year survival rate 94.7%) was obtained. H. pylori eradication was feasible and safe in the cases of low grade, stage I, and H. pylori-positive lymphoma, and allowed stomach preservation. Longer follow-up evaluation is required to determine the long-term efficacy and side effects of H. pylori eradication.
